Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

Idiopathic pulmonary fibrosis (IPF), the most common phenotype of IIPs ... To do this, they employed a marginal structural ...

Ascend, a global network of business professionals and executives working to advance Asian and Pacific Islander (API) equity in the workplace, has released the third report in its ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.

Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Personalized Care A nurse practitioner with NYU's pulmonary intervention team chronicles the NSCLC patient experience from diagnosis to ...

Our NICE Advice service will guide you there. Get reliable scientific advice and NHS insights, direct from NICE. We support companies seeking nationwide adoption of the best treatments and care. Our ...